[1] Desantis C, Ma JM, Bryan L, et al.Breast cancer statistics, 2013[J].CA Cancer J Clin, 2014, 64(1):52-62.DOI:10.3322/caac.21203.
[2] Siegel RL, Miller KD, Jemal A.Cancer statistics, 2015[J].CA Cancer J Clin, 2015, 65(1):5-29.DOI:10.3322/caac.21254.
[3] Sun Q.Multidisciplinary comprehensive therapy of breast cancer surgical treatment of the core role model[J].Chin J Breast Dis (Electronic Version), 2012, 6(1):9-15[2016-08-03].http://www.zhrxbzz.com/oa/DArticle.aspx?type=view&id=20120102.
[4] Eifel P, Axelson JA, Costa J, et al.National institutes of health consensus development conference statement:adjuvant therapy for breast cancer, November 1-3, 2000[J].J Natl Cancer Inst, 2001, 93(13):979-989.DOI:10.1093/jnci/93.13.979.
[5] Buscombe JR, Cwikla JB, Holloway B, et al.Prediction of the usefulness of combined mammography and scintimammography in suspected primary breast cancer using ROC curves[J].J Nucl Med, 2001, 42(1):3-8.
[6] Murphy IG, Dillon MF, Doherty AO, et al.Analysis of patients with false negative mammography and symptomatic breast carcinoma[J].J Surg Oncol, 2007, 96(6):457-463.DOI:10.1002/jso.20801.
[7] Liberman M, Sampalis F, Mulder DS, et al.Breast cancer diagnosis by scintimammography:a meta-analysis and review of the literature[J].Breast Cancer Res Treat, 2003, 80(1):115-126.DOI:10.1023/A:1024417331304.
[8] 王健, 宋秀宇, 徐文贵, 等.乳腺癌放射性核素分子成像研究进展[J].国际医学放射学杂志, 2015, 38(4):361-365.DOI:10.3874/j.issn.1674-1897.2015.04.Z0411.
Wang J, Song XY, Xu WG, et al.The research progress of radionuclide molecular imaging for breast cancer[J].Int J Med Radiol, 2015, 38(4):361-365.  doi: 10.3874/j.issn.1674-1897.2015.04.Z0411
[9] 何小江, 黄劲雄, 陈贵兵, 等.99mTc-奥曲肽和X线钼靶诊断乳腺癌[J].中国医学影像技术, 2009, 25(10):1892-1895.DOI:10.3321/j.issn:1003-3289.2009.10.044.
He XJ, Huang JX, Chen GB, et al.99mTc-octreotide scintigraphy and planar X-ray mammography diagnosis of breast cancer[J].Chin J Med Imaging Technol, 2009, 25(10):1892-1895.  doi: 10.3321/j.issn:1003-3289.2009.10.044
[10] 张金山, 邓念英, 李舜, 等.99Tcm-octreotide显像在乳腺癌诊断中的应用[J].中华核医学杂志, 2004, 24(1):24-26.DOI:10.3760/cma.j.issn.2095-2848.2004.01.008.
Zhang JS, Deng NY, Li S, et al.Primary application of 99Tcm-octreotide imaging in the diagnosis of breast cancer[J].Chin J Nucl Med, 2004, 24(1):24-26.  doi: 10.3760/cma.j.issn.2095-2848.2004.01.008
[11] 黄为昆, 李国新, 齐德林.乳腺癌及腋淋巴结转移99Tcm-tetrofosmin与99Tcm-MIBI显像的对比研究[J].中华核医学杂志, 2001, 21(2):95-96.DOI:10.3760/cma.j.issn.2095-2848.2001.02.015.
Huang WK, Li GX, Qi DL.A clinical comparative study of 99Tcm-tetrofosmin with 99Tcm-MIBI in breast carcinoma and axillary lymph node metastases[J].Chin J Nucl Med, 2001, 21(2):95-96.  doi: 10.3760/cma.j.issn.2095-2848.2001.02.015
[12] Haubner RH, Wester HJ, Weber WA, et al.Radiotracer-based strategies to image angiogenesis[J].Q J Nucl Med, 2003, 47(3):189-199.
[13] 江泽飞, 邵志敏, 徐兵河.人表皮生长因子受体2阳性乳腺癌临床诊疗专家共识[J].中华肿瘤杂志, 2010, 32(2):158-160.DOI:10.3760/cma.j.issn.0253-3766.2010.02.018.
Jiang ZF, Shao ZM, Xu BH.Diagnosis and treatment of HER-2-positive breast cancer:expert consensus of the chinese anti-cancer association[J].Chin J Oncol, 2010, 32(2):158-160.  doi: 10.3760/cma.j.issn.0253-3766.2010.02.018
[14] Hood JD, Cheresh DA.Role of integrins in cell invasion and migration[J].Nat Rev Cancer, 2002, 2(2):91-100.DOI:10.1038/nrc727.
[15] Desgrosellier JS, Cheresh DA.Integrins in cancer:biological implications and therapeutic opportunities[J].Nat Rev Cancer, 2010, 10(1):9-22.DOI:10.1038/nrc2748.
[16] Niu G, Chen X.Why integrin as a primary target for imaging and therapy[J].Theranostics, 2011, 1(1):30-47.DOI:10.7150/thno/v01p0030.
[17] Shi JY, Wang LJ, Kim YS, et al.99mTcO(MAG2-3G3-dimer):a new integrin αvβ3-targeted SPECT radiotracer with high tumor uptake and favorable pharmacokinetics[J].Eur J Nucl Med Mol Imaging, 2009, 36(11):1874-1884.DOI:10.1007/s00259-009-1166-1.
[18] Wang L, Shi J, Kim YS, et al.Improving tumor-targeting capability and pharmacokinetics of 99mTc-labeled cyclic RGD dimers with PEG4 linkers[J].Mol Pharm, 2009, 6(1):231-245.DOI:10.1021/mp800150r.
[19] Shi J, Kim YS, Chakraborty S, et al.2-Mercaptoacetylglycylglycyl (MAG2) as a bifunctional chelator for 99mTc-labeling of cyclic RGD dimers:effect of technetium chelate on tumor uptake and pharmacokinetics[J].Bioconjug Chem, 2009, 20(8):1559-1568.DOI:10.1021/bc9001739.
[20] Liu Z, Jia B, Shi J, et al.Tumor uptake of the RGD dimeric probe 99mTc-G3-2P4-RGD2 is correlated with integrin αvβ3 expressed on both tumor cells and neovasculature[J].Bioconjug Chem, 2010, 21(3):548-555.DOI:10.1021/bc900547d.
[21] Jia B, Liu Z, Zhu Z, et al.Blood clearance kinetics, biodistribution, and radiation dosimetry of a kit-formulated integrin αvβ3-selective radiotracer 99mTc-3PRGD2 in non-human primates[J].Mol Imaging Biol, 2011, 13(4):730-736.DOI:10.1007/s11307-010-0385-y.
[22] Zhu Z, Miao W, Li Q, et al.99mTc-3PRGD2 for integrin receptor imaging of lung cancer:a multicenter study[J].J Nucl Med, 2012, 53(5):716-722.DOI:10.2967/jnumed.111.098988.

Liu L, Song Y, Gao S, et al.99mTc-3PRGD2 scintimammography in palpable and nonpalpable breast lesions[J/OL].Mol Imaging, 2014, 13:1-7[2016-08-03].https://www.ncbi.nlm.nih.gov/pubmed/?term=24825112.DOI:10.2310/7290.2014.00010.


Ma Q, Chen B, Gao S, et al.99mTc-3P4-RGD2 scintimammography in the assessment of breast lesions:comparative study with 99mTc-MIBI[J/OL].PLoS One, 2014, 9(9):e0108349[2016-08-03].http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0108349.DOI:10.1371/journal.pone.0108349.


Chen Q, Ma Q, Chen M, et al.An exploratory study on 99mTc-RGD-BBN peptide scintimammography in the assessment of breast malignant lesions compared to 99mTc-3P4-RGD2[J/OL].PLoS One, 2015, 10(4):e0123401[2016-08-03].https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4388716.DOI:10.1371/journal.pone.0123401.

[26] Zhou Y, Kim YS, Chakraborty S, et al.99mTc-labeled cyclic RGD peptides for noninvasive monitoring of tumor integrin αVβ3 expression[J].Mol Imaging, 2011, 10(5):386-397.DOI:10.2310/7290.2011.00006.
[27] Ma Q, Ji B, Jia B, et al.Differential diagnosis of solitary pulmonary nodules using 99mTc-3P4-RGD2 scintigraphy[J].Eur J Nucl Med Mol Imaging, 2011, 38(12):2145-2152.DOI:10.1007/s00259-011-1901-2.
[28] Percha B, Nassif H, Lipson J, et al.Automatic classification of mammography reports by BI-RADS breast tissue composition class.J Am Med Inform Assoc, 2012, 19(5):913-916.DOI:10.1136/amiajnl-2011-000607.
[29] Palmedo H, Schomburg A, Grünwald F, et al.Technetium-99m-MIBI scintimammography for suspicious breast lesions[J].J Nucl Med, 1996, 37(4):626-630.
[30] Scopinaro F, Schillaci O, Ussof W, et al.A three center study on the diagnostic accuracy of 99mTc-MIBI scintimammography[J].Anticancer Res, 1997, 17(3B):1631-1634.
[31] Pichler BJ, Kneilling M, Haubner R, et al.Imaging of delayed-type hypersensitivity reaction by PET and 18F-galacto-RGD[J].J Nucl Med, 2005, 46(1):184-189.
[32] Mcdonald DM, Choyke PL.Imaging of angiogenesis:from microscope to clinic[J].Nat Med, 2003, 9(6):713-725.DOI:10.1038/nm0603-713.
[33] Horton MA.The αvβ3 integrin "vitronectin receptor"[J].Int J Biochem Cell Biol, 1997, 29(5):721-725.DOI:10.1016/S1357-2725(96)00155-0.